CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Mayinglong Pharmaceutical Group Co Ltd Company Snapshot
Mayinglong Pharmaceutical Group Co Ltd operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mayinglong Pharmaceutical Group Co Ltd with three other companies in this sector in CHINA : Xiangxue Pharmaceutical Co Ltd (2019 sales of 2.79 billion Chinese Renmimbi [US$408.29 million] of which 49% was Chinese Herbal Medicines), Autobio Diagnostics Co Ltd (2.68 billion Chinese Renmimbi [US$392.64 million] of which 97% was In vitro diagnosis), and Guizhou Bailing Group Pharmaceutical Company Limited (2.85 billion Chinese Renmimbi [US$417.72 million] of which 84% was Industry).

Sales Analysis. Mayinglong Pharmaceutical Group Co Ltd reported sales of 2.70 billion Chinese Renmimbi (US$396.33 million) for the year ending December of 2019. This represents an increase of 23.1% versus 2018, when the company's sales were 2.20 billion Chinese Renmimbi. Sales of Pharmaceutical Circulation saw an increase that was more than double the company's growth rate: sales were up 47.7% in 2019, from 737.17 million Chinese Renmimbi to 1.09 billion Chinese Renmimbi. Not all segments of Mayinglong Pharmaceutical Group Co Ltd experienced an increase in sales in 2019: sales of Undistributed Amount fell 68.9% to 25,896.81 Chinese Renmimbi. (However, this segment's sales were only a very small portion of the company's overall sales). Mayinglong Pharmaceutical Group Co Ltd also experienced decreases in sales in the Hospital Diagnosis and Treatment (down 22.7% to 159.82 million Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Mayinglong Pharmaceutical Group Co Ltd
  Stock Performance Chart for Mayinglong Pharmaceutical Group Co Ltd
 
  Stock Data: Recent Stock Performance:
  Current Price (9/25/2020): 20.92
(Figures in Chinese Renmimbi)
1 Week -6.1%   13 Weeks -17.2%  
4 Weeks -0.5%   52 Weeks 24.4%  
 
Mayinglong Pharmaceutical Group Co Ltd Key Data:
  Ticker: 600993 Country: China
  Exchanges: SHG Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2019 Sales 2,704,583,763
(Year Ending Jan 2020).
Employees: 3,079
  Currency: Chinese Renmimbi Market Cap: 9,017,647,400
  Fiscal Yr Ends: December Shares Outstanding: 431,053,891
  Share Type: A Shares Closely Held Shares: 161,091,304
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.